Circadian genes influence a variety of biological processes that are important in prostate tumorigenesis including metabolism. To determine if variants in circadian genes alter prostate cancer risk, we genotyped five variants in five circadian genes in a population-based case-control study conducted in China (187 cases and 242 controls). These variants included CRY2 rs1401417:G4C, CSNK1E rs1005473:A4C, NPAS2 rs2305160:G4A, PER1 rs2585405:G4C and PER3 54-bp repeat length variant. Men with the cryptochrome 2 (CRY2)-variant C allele had a significant 1.7-fold increased prostate cancer risk (95% confidence interval (CI), 1.1-2.7) relative to those with the GG genotype. This risk increased to 4.1-fold (95% CI, 2.2-8.0) in men who also had greater insulin resistance (IR) as compared to men with the GG genotype and less IR. In contrast, among men with less IR, the NPAS2-variant A allele was associated with decreased prostate cancer risk (odds ratio ¼ 0.5, 95% CI, 0.3-1.0) as compared to the GG genotype. Our findings, although in need of confirmation, suggest that variations in circadian genes may alter prostate cancer risk and some biological processes may modify this effect.
Introduction
Circadian rhythms are the daily oscillations of multiple biological processes driven by endogenous clocks with or without external cues. These rhythms not only maintain human sleep patterns but influence biological processes such as metabolism [1] [2] [3] [4] and sex hormone biosynthesis and action; 5 both of which are important for prostate tumorigenesis. Epidemiologic data from occupational cohorts suggest that circadian rhythm disruptions increase the risk for prostate cancer. For example, rotating shift workers had a higher risk of prostate cancer as compared with only day-or only night-shift workers. 6, 7 In addition, male airline pilots had an excess risk of prostate cancer [8] [9] [10] that increased with the increasing number of flight hours. 10 Although compelling, these data represent indirect associations between circadian rhythms and prostate cancer; no underlying molecular mechanism thus far has been identified.
Nine identified genes control endogenous circadian rhythms via a transcription-translation feedback loop and include CLOCK, neuronal PAS domain protein 2 (NPAS2), aryl hydrocarbon receptor nuclear translocator-like (ARNTL), cryptochrome 1 (CRY1), cryptochrome 2 (CRY2), period 1 (PER1), period 2 (PER2), period 3 (PER3) and casein kinase 1-epsilon (CSNK1E). 11 Three recent studies show that variants in circadian genes are associated with altered cancer risk. In breast cancer, a PER3 repeat length polymorphism was associated with a 1.7-fold increased risk (95% confidence interval (CI), 1.0-3.0) among premenopausal women. 12 In contrast, women with the heterozygous genotype of NPAS2 rs2305160:G4A single nucleotide polymorphism (SNP) had significantly reduced risk of breast cancer as compared to those with the common homozygous GG genotype (odds ratio (OR) ¼ 0.61, 95% CI, 0.46-0.81, P ¼ 0.001). 13 The same NPAS2-SNP was also linked to a reduced risk for nonHodgkin's lymphoma (OR ¼ 0.66, 95% CI, 0.51-0.85) with the association being the strongest with the B-cell lymphoma subtype (OR ¼ 0.61, 95% CI, 0.47-0.80). 14 These findings suggest that the variation in circadian genes may affect the risk of a variety of cancers including that of the prostate. 15 One possible mechanism by which circadian genes may influence prostate cancer risk is through their effect on metabolism and energy balance. In mice with mutated Clock or deleted Bmal1 (a homologue of human ARNTL), gluconeogenesis was suppressed or abolished, respectively. 2 In addition, insulin injections elicited hypoglycemic responses in the mutant mice that were not seen in their wild-type counterparts. Furthermore, Clock mutant mice that had a greatly attenuated diurnal feeding rhythm, were hyperphagic and obese, and developed metabolic syndrome that included hypoinsulinemia. 3 Since many of the phenotypes described for Clock and Bmal1 mutant mice are also the putative risk factors for prostate cancer, [16] [17] [18] [19] it is important to determine if circadian genes can interact with indicators of obesity and insulin resistance in modifying prostate cancer risk.
In this study, we examined the relationships between five variants of five circadian genes and prostate cancer risk in a population-based case-control study conducted in Shanghai, China. Three of the five variants were chosen based on putative function and included PER1 rs2585405:G4C (Ala962Pro), NPAS2 rs2305160:G4A (Ala394Thr) and PER3 54-bp repeat length variant in exon 18; the PER3 and NPAS2 polymorphisms were associated with other cancers in previous studies. [12] [13] [14] Two other variants were chosen because they had minor allele frequencies greater than 5% and included CRY2 rs1401417:G4C and CSNK1E rs1005473:A4C. In addition, we examined if body size and insulin resistance could influence the effect that circadian gene variation has on the prostate cancer risk.
Materials and methods

Study population
Details of this population-based case-control study conducted in Shanghai, China have been reported previously. [16] [17] [18] 20, 21 In brief, newly diagnosed primary prostate cancer cases (International Classification of Diseases 9 code 185) were identified through a rapid reporting system established between the Shanghai Cancer Institute and 28 collaborating hospitals in urban Shanghai, between 1993 and 1995. In-person interviews were conducted, using a structured questionnaire, to collect demographic characteristics information that included smoking history and alcohol use. Anthropometric measurements were also obtained as part of the interview. Of the 268 eligible cases (95% of the cases were diagnosed in Shanghai during the study period), 243 (91%) were interviewed. Male controls who were randomly selected from the general population, matched to the index case by age (within 5 years). Of the 495 eligible controls, 472 (95%) were interviewed. Neither cases nor controls had prior history of cancer. The study was approved by the Institutional Review Boards at the National Cancer Institute and the Shanghai Cancer Institute.
Biological specimen collection and genetic analysis
As part of the interview, 200 cases (82% of those interviewed) and 330 controls (70%) provided 20 ml of fasting blood for the study. For this study, biospecimens were available for 187 cases and 242 controls. The overnight fasting blood samples were used to measure insulin and glucose in the laboratory of FZ Stanczyk at the University of Southern California, as reported previously. 18 Genomic DNA extracted from the buffy coat was used for genotyping five variants in five circadian genes in the laboratory of Y Zhu at Yale University. Approximately 5% of the samples were duplicated for quality control and two reviewers independently scored the genotypes to confirm the results. The PER3 variant is a repeat polymorphism with four or five copies of a 54-bp repetitive sequence in exon 18 (GenBank accession no. AB047686) 22, 23 and is located on chromosome 17p13.1. Details of the PCR-based sequence-length polymorphism analysis are described elsewhere. 12 The other four variants are SNPs of CRY2 (rs1401417:G4C, chromosome 11p11.2), CSNK1E (rs1005473:A4C, chromosome 22q13.1), NPAS2 (rs2305160:G4A, chromosome 2q11.2) and PER1 (rs2585405:G4C, chromosome 17p13.1). TaqMan Assays-on-Demand primers and probes (Applied Biosystems, Foster City, CA, USA) were used according to the manufacturer and have been previously described.
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Statistical analyses
All statistical analyses were carried out using STATA statistical software (StataCorp LP, College Station, TX, USA). Allele frequencies for all gene variants in the controls were analysed for Hardy-Weinberg equilibrium. Unconditional logistic regression analyses were used to calculate ORs and 95% CIs. The OR and 95% CI are not given if either cases or controls have less than five individuals. All models were adjusted for age as a categorical variable with age categories of p65, 66-75 and 475. Due to limited sample size, median values from controls were used to define categories of waist-tohip ratio, body mass index and insulin resistance (IR) as defined by the homeostasis model assessment (HOMA) where appropriate. HOMA is calculated by the equation: HOMA ¼ fasting insulin (mU ml -1 ) Â glucose (mmol l -1 )C 22.5. For interaction analyses, genotypes were dichotomized based on the presence or absence of the variant allele due to limited sample size. In addition, dummy variables representing the different combinations of genotype and IR were used in the models to determine ORs and 95% CIs. Furthermore, cross product terms were used to determine P-interaction. All tests for statistical significance were two-tailed with a ¼ 0.05.
Results
Selected characteristics of cases and controls are shown in Table 1 . Cases and controls were of similar age and had similar body mass indices. Cases tended to be better educated (P-trend ¼ 0.04), were less likely to be smokers (P-trend ¼ 0.06), were less likely to use alcohol (Ptrendo0.01) and had higher median waist-to-hip ratio and HOMA (both Po0.01) than controls. The cases had a median prostate specific antigen (PSA) level of 89.5 ng ml -1 and nearly two-thirds of them had advanced cancer (regional/remote).
Circadian genes and prostate cancer LW Chu et al Allele frequency distributions for the five circadian gene variants in the controls were in Hardy-Weinberg equilibrium (P40.05; data not shown). The ORs and 95% CIs for prostate cancer associated with variants of circadian genes are presented in Table 2 . Men with the CRY2-variant C allele had a significant 1.7-fold increased risk (95% CI, 1.1-2.6) for prostate cancer as compared with those with the GG genotype. In addition, suggestive increase and decrease in risk are seen in men with variants of PER3 (OR 4-/5-þ 5-/5-repeat ¼ 1.3, 95% CI, 0.9-2.1 versus 4-/4-repeat genotype) and NPAS2 (OR GA þ AA ¼ 0.8, 95% CI 0.5-1.1 versus GG genotype) respectively. We also observed a decreased risk associated with the heterozygous NPAS2 genotype (OR GA ¼ 0.6, 95% CI, 0.4-1.0 versus the GG genotype) but an increased risk associated with the homozygous variant genotype (OR AA ¼ 2.0, 95% CI, 0.9-4.4 versus the GG genotype); this difference in risks may be due to small sample size. Risk estimates for all gene variants were similar for advanced and non-advanced tumors (data not shown). Further adjustment for waist-to-hip ratio, body mass index, IR, or alcohol use did not materially change the results (data not shown). Table 3 shows prostate cancer risk in relation to circadian gene polymorphisms by HOMA as a measure of IR; men with HOMAo1.44 had less IR while those with HOMAX1.44 had greater IR. In general, greater IR conferred an approximate 2-fold higher risk for prostate cancer, which is consistent with a previous study in the study population; 18 this effect was independent of circadian gene variants. However, men with greater IR and the CRY2-variant C allele had a 4.1-fold increased risk (95% CI, 2.2-8.0) for prostate cancer relative to men with less IR and the GG genotype. Excess risk for prostate cancer was also seen in the men with greater IR and variants of CSNK1E (OR ¼ 2.7, 95% CI, 1.2-5.9) and PER3 (OR ¼ 3.1, 95% CI, 1.7-5.7) relative to those with the wild type and lower IR. In contrast, within the group of men with less IR those with the NPAS2-variant A allele had reduced prostate cancer risk (OR ¼ 0.5, 95% CI, 0.3-1.0) as compared to men with GG genotype; this effect was not detected in the group of men with greater IR. However, interactions between IR and the circadian gene variants were not significant due to small numbers. No differences in risk were seen in stratification analyses using body mass index and waist-to-hip ratio as indicators of body size.
Discussion
In this population-based case-control study, we found that an intronic CRY2 variant was significantly associated with a 1.7-fold risk of prostate cancer and this risk was more pronounced for men who also had a greater IR. Men with a greater IR and with the variant alleles of CSNK1E or PER3 also had excess prostate cancer risk relative to those with less IR and with the wild Circadian genes and prostate cancer LW Chu et al type alleles. In contrast, among men with less IR, a reduced prostate cancer risk was associated with the NPAS2-variant allele that was not seen among men with greater IR. These results provide the first evidence supporting the circadian gene hypothesis in prostate tumorigenesis. 15 Findings from animal studies support the hypothesis that circadian genes may affect cancer susceptibility. For example, mice with the mutant PER2 gene had impaired DNA damage responses to g-irradiation and were more cancer-prone as compared to their wild type counterparts. 24 The impaired DNA damage response was due to the deregulation of circadian gene-controlled expression of cyclin D1, cyclin A2, Mdm2, Gadd45a and Myc, all of which are involved in the cell cycle regulation and tumor suppression. Interestingly, the human MYC gene resides close to the 8q24 region that was found to be strongly associated with prostate cancer risk in recent genomewide association studies of prostate cancer. [25] [26] [27] [28] Although no in vivo studies directly assessed the relationship between CRY2 and cancer, it is plausible that variations or mutations of CRY genes may alter cancer risk in a manner similar to that of PER2 because both are negative regulators of the circadian pathway. Since animal studies also suggest that circadian genes may be tumor suppressors, disruptions to human circadian genes might increase cancer risk by interfering with or inhibiting their tumor suppression activity. 11 Data from the recently released and publicly available NCI genome-wide association study on prostate cancer also support our hypothesis that variants of circadian genes may alter prostate cancer risk. The NCI cancer genetic markers of susceptibility (CGEMS) project genotyped 550 000 SNPs on 1182 prostate cancer cases and 1174 controls from the prostate, lung, cervical and ovarian cancer screening trial. 29 A total of 155 SNPs from the nine circadian genes were included in the CGEMS project. Eight of the 155 SNPs, located on four genes, CRY1 (2 SNPs), CRY2 (1 SNP), CSNK1E (2 SNPs) and NPAS2 (3 SNPs) were significantly associated with altered prostate cancer risk (global Pp0.05 for all SNPs) including three with global Pp0.01. One SNP was in common between this study and that of CGEMS (NPAS2 rs2305160) and results from both studies show a reduction in the prostate cancer risk associated with this SNP; in CGEMS, this finding was borderline significant (global P ¼ 0.07) as a main effect similar to our findings. Since we found that risk-estimates may be attenuated due to interactions with other potential risk factors (such as by IR), it is likely that the effects of the circadian gene variants on prostate cancer risk in the CGEMS study are also modified by similar interactions.
Although our results showing an effect of the interaction between IR and variants in circadian genes on prostate cancer risk should be considered merely suggestive, it is possible that metabolism acts as a link between circadian genes and IR. 4 In vitro findings show that cell-redox flux, an indicator of a cell's energy state, can alter the core circadian machinery 1 but in vivo studies indicate that alterations in this molecular clock may alter Circadian genes and prostate cancer LW Chu et al cell metabolism as well. The Clock mutant mice that had attenuated diurnal feeding rhythms were hyperphagic and obese, and developed several metabolic syndrome phenotypes including hyperglycemia and hypoinsulinemia. 3 In addition, mice with mutant Clock or deleted Bmal1 (a homologue of human ARNTL) had impaired gluconeogenesis which resulted in altered daily fluctuations of plasma glucose and triglycerides. 2 Although a chronic high-fat diet amplified the daily oscillations in glucose tolerance and insulin sensitivity, these mutant mice were protected against the development of frank diabetes. Because obesity is a major hypothesis for prostate tumorigenesis, [16] [17] [18] [19] 30, 31 it is plausible that the interplay between circadian genes and metabolic processes such as insulin-action may also contribute to altering prostate cancer risk.
An alternative mechanism by which circadian genes may affect the prostate cancer risk (that was not explored in this study) is through their effect on sex hormone levels in serum, in particular androgens, 15 because prostate cancer is a hormone-dependent malignancy. 19 The central circadian clock in the brain influences steroid hormone secretion via the hypothalamic-pituitarygonadal axis. In a mouse model, Clock mutants lacked the appropriate circadian signals that are required to coordinate the hypothalamic-pituitary-gonadal axis, which resulted in disrupted reproduction. 32 In men with normal sleep patterns and those with obstructive sleep apnea, sleep fragmentation resulted in significant reductions in nocturnal testosterone; 33,34 similar disruptions in testosterone rhythm are also seen in prostate cancer patients. 35 Since variants in PER genes are associated with delayed sleep phase syndrome and extreme diurnal preference, 22, 23, 36, 37 it is plausible that variants in PER genes are associated with different serum steroid hormone levels thus affecting risk for hormone-related cancers. Interestingly, the PER3 structural variant that was associated with an increased prostate cancer risk in a subgroup of men in this study was also linked to an increased risk for breast cancer among premenopausal women. 12 In addition, NPAS2, the homolog to Clock, was recently shown to interact with the androgen receptor in vitro. 38 Taken together, these data support the hypothesis that circadian genes may modify the risk of hormonally mediated cancers through regulating sex hormones in serum and their action on cells. 39 Therefore, future studies should also examine the relationship between circadian genes and sex hormones.
On a chromosomal level, several circadian genes reside on regions of chromosomes that are frequently altered or near the genes that are related to certain genetic events in prostate cancer progression. For example, PER1 resides on chromosome 17p (at band 17p13), which is one of the most frequently lost regions of the genome found in prostate tumors. 40 Chromosome 17p13 also harbors the gene encoding the tumor suppressor p53, sex hormone binding globulin and aurora kinase B, all of which have been associated with Circadian genes and prostate cancer LW Chu et al prostate cancer. [41] [42] [43] Two other circadian genes reside near the genes that encode UDP glucuronosyltransferases (UGT), which are involved in clearance of steroid hormones. PER2 and three UGT genes (UGT1A1, UGT1A8 and UGT1A9) reside on chromosome 2q37 while Clock (on 4q12) is near UGT2B15 and UGT2B17 on 4q13. The proximity of circadian genes to genes important in prostate cancer progression suggests that cancer risk variants of the genes may have high linkage disequilibrium with each other and/or the genes may share common transcriptional regulatory elements. Thus, future studies should also investigate the relationship between circadian genes and their neighboring genes.
Strengths of our study include minimal selection and survival biases because over 90% of eligible cases participated in the study and most of the cases were interviewed within 21 days of diagnosis. In addition, close to 75% of the study participants gave blood for the study and thus it is unlikely that observed allele frequencies are related to response status among cases and controls. Furthermore, quality control measures were taken to minimize misclassification of genotyping including the confirmation of genotyping results by two independent reviewers.
Limitations of the study should be noted. Since the Shanghai population is relatively homogeneous, we have limited generalizability. We also do not have data on sleep patterns and light exposure, which could also affect circadian rhythmicity and interact with genetic susceptibility. Future studies should include these variables in data collection and analyses. In addition, this study population is rather lean and may not be ideal for addressing the link between obesity and prostate cancer although age-adjusted prevalence of IR or metabolic syndrome in Chinese men is notable at 10.1%. 44 Furthermore, the variants analyzed in this study provided very limited gene coverage. Based on data from the International HapMap Consortium, 45 approximately 275 tag SNPs are needed adequately to cover the nine circadian genes. In addition, there are about 40 putatively functional SNPs that may also be of interest. Therefore, to characterize the role of circadian gene variants in prostate cancer risk more precisely, future studies will need to examine over 300 SNPs in these nine genes.
In conclusion, our population-based study conducted in a low-risk population suggests that polymorphisms in circadian genes may affect prostate cancer risk and this risk may be modified by some biological processes such as IR. Future studies with larger sample size and more complete gene coverage are needed to confirm our findings. In addition, biological processes such as hormone biosynthesis and action should be examined for their possible roles in modifying the relationship between circadian genes and prostate cancer risk.
